Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-10-31 12:31:322019-10-31 13:53:48Dicerna, Roche Partner on RNA Silencing for Hep B